"Alzheimer's Research UK stated that too few UK patients are participating in clinical trials due to delayed or non-specific diagnoses, risking their access to new treatments."
"Dr. Sheona Scales emphasized that without a large and diverse range of patients for trials, the UK risks missing out on the next generation of Alzheimer's treatments."
"More than 32 million people worldwide have Alzheimer's disease, yet one in three living with the condition in the UK do not have a formal diagnosis."
"Recent anti-amyloid medicines like lecanemab and donanemab have been approved, but their benefits are slight and neither drug is considered cost-effective for the NHS."
Alzheimer's Research UK reported that many patients miss out on experimental treatments due to delayed or inaccurate diagnoses. Despite a record number of clinical trials, participation remains low. The charity emphasizes the need for a diverse patient pool to ensure access to next-generation treatments. Over 32 million people globally have Alzheimer's, with many lacking formal diagnoses. Recent anti-amyloid drugs have shown promise in slowing disease progression, but their cost-effectiveness remains in question, and recent reviews have sparked debate about their overall impact.
Read at www.theguardian.com
Unable to calculate read time
Collection
[
|
...
]